US based drug firm Mylan today said its Indian arm has received nod from the country's drug regulator DCGI to market its antiretroviral drug Avonza.
Mylan Pharmaceuticals Private Ltd, a subsidiary of Mylan N V, has received marketing authorisation from the Drug Controller General of India (DCGI) for its antiretroviral drug Avonza, the company said in a statement.
The product is recommended by the World Health Organisation (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS, it added.
"Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high quality ARVs," Mylan President Rajiv Malik said.
Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs, he added.
The company's comprehensive ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and paediatric formulations, Mylan said.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.